Repurposing FDA-approved drugs

Background

We supported an innovative project focused on repurposing FDA-approved, off-patent drugs for the treatment of non-melanoma skin cancer. This project, funded by Almirall Pharmaceutical Pty Ltd, aimed to address the significant time and financial challenges associated with de novo drug development.

‍

Objective

To identify existing drugs that could be effectively repurposed to treat skin conditions, reducing the costs and timelines associated with new drug development while ensuring efficacy and market readiness.

‍

Approach

Leveraging deep expertise in drug repurposing strategies, we provided guidance on:

• identifying and evaluating FDA-approved drugs for new applications in treating non-melanoma skin cancer
• designing clinical trials to validate the efficacy of these repurposed drugs
• streamlining regulatory pathways to accelerate market approval and reduce costs.

Results

• It was demonstrated how existing drugs could be modified and applied to new indications to significantly reduce development time and costs.
• Clinical trials then validated the efficacy of these repurposed drugs for treating non-melanoma skin cancer.
• Investigations yielded promising results for commercialization.

Key takeaways

• Our strategic guidance enabled the successful identification and repurposing of existing drugs for new skin cancer treatments.
• The project highlighted how drug repurposing can bypass traditional drug development challenges, with the potential to achieve faster regulatory approval and reduced financial burdens.
• Efficacy in clinical trials provided a strong foundation for commercialization and market success.